Introduction {#Sec1}
============

Acute kidney injury (AKI) occurs in up to 30%^[@CR1]^ of patients undergoing adult cardiac surgery, and it is associated with prolonged respiratory support and intensive care unit (ICU) stay, may increase the risk of short-term and long-term death^[@CR2]--[@CR4]^, especially in those requiring renal replacement therapy (RRT)^[@CR5]^. Moreover, with increasing morbidity (such as advanced age, diabetes mellitus, and complex surgical procedures) in this population, postoperative AKI is becoming an important issue in adult patients undergoing cardiac surgery^[@CR6],\ [@CR7]^.

Remote ischemic preconditioning (RIPC) is a noninvasive, feasible and low-cost approach elicited by several brief episodes of ischemia and reperfusion (I/R) in a remote organ (a limb using a blood pressure cuff in this study) to offer protection from subsequent ischemic injury^[@CR8]^. RIPC has proven to be beneficial to protect against I/R injury of various organs^[@CR9]^ including the kidney^[@CR10]--[@CR13]^ in numerous animal studies. In human, RIPC has also been shown to prevent reperfusion-induced endothelial dysfunction^[@CR14]--[@CR16]^, and offers a promising strategy for reducing the burden associated with AKI in patients undergoing cardiac surgery.

Several randomized controlled trials (RCTs)^[@CR17]--[@CR22]^ have reported on the impact of RIPC on preventing AKI, but the results are mixed. Recently, several striking large-scale RCTs^[@CR23]--[@CR27]^ with mixed findings have added to the available evidence for the renoprotective effect of RIPC in adult cardiac surgery. Therefore, we aimed to conduct an up-to-date meta-analysis to comprehensively evaluate the effect of RIPC on the incidence of AKI and identify the related potential influential factors in adults undergoing cardiac surgery.

Results {#Sec2}
=======

Study characteristics {#Sec3}
---------------------

Figure [1](#Fig1){ref-type="fig"} shows the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow chart for the RCTs screening and selection process for inclusion in this study. 21 RCTs^[@CR17]--[@CR37]^ with a total of 6302 patients met the inclusion criteria. 6 RCTs were conducted for isolated coronary artery bypass graft (CABG)^[@CR17],\ [@CR22],\ [@CR28]--[@CR31]^, 5 RCTs were done in isolated valve surgery^[@CR20],\ [@CR21],\ [@CR34],\ [@CR35],\ [@CR37]^, and 10 RCTs included a combination of CABG and valve surgery^[@CR18],\ [@CR19],\ [@CR23]--[@CR27],\ [@CR32],\ [@CR33],\ [@CR36]^. The ischemic protocol (cycles × I/R) was 3 × 5 min/5 min in 11 RCTs^[@CR17]--[@CR19],\ [@CR22],\ [@CR26],\ [@CR28],\ [@CR29],\ [@CR32],\ [@CR35]--[@CR37]^, 4 × 5 min/5 min in 7 RCTs^[@CR24],\ [@CR25],\ [@CR27],\ [@CR30],\ [@CR31],\ [@CR33],\ [@CR34]^, 3 × 10 min/10 min in 2 RCTs^[@CR20],\ [@CR21]^, and 2 × 5 min/5 min in 1 RCT^[@CR23]^. The upper limb was used in 11 RCTs^[@CR17],\ [@CR19],\ [@CR22]--[@CR29],\ [@CR32],\ [@CR35]^, the lower limb in 3 RCTs^[@CR18],\ [@CR20],\ [@CR37]^, the thigh in 6 RCTs^[@CR21],\ [@CR30],\ [@CR31],\ [@CR33],\ [@CR34],\ [@CR36]^, the combined of upper limb and thigh in 1 RCT^[@CR23]^. The incidence of AKI was reported in 17 RCTs^[@CR17]--[@CR27],\ [@CR31]--[@CR36]^ (AKI stage I in 11 RCTs^[@CR17]--[@CR19],\ [@CR22]--[@CR27],\ [@CR32],\ [@CR36]^), the need for RRT in 19 RCTs^[@CR17]--[@CR20],\ [@CR22]--[@CR33],\ [@CR35]--[@CR37]^, mortality in 19 RCTs^[@CR17]--[@CR19],\ [@CR21]--[@CR36]^, MV duration in 13 RCTs^[@CR17],\ [@CR20]--[@CR22],\ [@CR26]--[@CR29],\ [@CR31]--[@CR35]^, ICU stay in 16 RCTs^[@CR17],\ [@CR20]--[@CR23],\ [@CR25]--[@CR29],\ [@CR31],\ [@CR33]--[@CR37]^, and hospital length of stay (LOS) in 16 RCTs^[@CR17]--[@CR23],\ [@CR25]--[@CR28],\ [@CR31],\ [@CR33],\ [@CR34],\ [@CR36],\ [@CR37]^. 19 RCTs^[@CR17]--[@CR21],\ [@CR23]--[@CR28],\ [@CR30]--[@CR37]^ had a Jadad score of more than 3. Further details of RCTs characteristics and the RIPC protocol used in each RCT are provided in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Figure 1Screening and selection process of eligible RCTs for inclusion in this meta-analysis according to PRISM. Table 1Study design in all included RCTs.StudyCountrySurgeryPts. No. RIPC vs CtrlRIC protocolRIC initiation to CPBPlacebo ControlRenal EndpointsBaseline Creatinine level (mg/dl)AKI DefinitionF-upJadad scoreCycles × I/RCuff pressureRahman^[@CR17]^UKCABG (On)42 vs 383 × 5 min/5 min at upper limb200 mmHg74 minsYesAKI, RRT, Mortality1.10SCr↑ \>0.5 mg/dl30 d5Thielmann^[@CR28]^GermanCABG (On)27 vs 263 × 5 min/5 min at upper limbVenugopal^[@CR19]^UKCombined38 vs 403 × 5 min/5 min at upper limb200 mmHg\<45\~60 minsYesAKI, RRT, Mortality0.95AKIN30 d4Zimmerman^[@CR18]^USACombined59 vs 593 × 5 min/5 min at thigh200 mmHgN.ANoAKI, RRT, Mortality0.94AKINIn-hospital5Choi^[@CR20]^KoreaValve38 vs 383 × 10 min/10 min at thigh250 mmHg\>70 minsYesAKI, RRT0.915AKINIn-hospital5Lomivorotov^[@CR29]^RussianCABG (On)40 vs 403 × 5 min/5 min at upper limb200 mmHg30\~50 minsYesRRTN.ARRTIn-hospital1Lucchinetti^[@CR30]^CanadaCABG (On)27 vs 284 × 5 min/5 min at thigh300 mmHgN.AYesRRT1.01RRT6 mon5Hong^[@CR31]^KoreaCABG (Off)35 va 354 × 5 min/5 min at thigh200 mmHg18 minsYesRRT, Mortality1.10RRT30 d3Kim^[@CR21]^KoreaValve27 vs 273 × 10 min/10 min at thigh250 mmHgPre- plus Post-CPBYesAKI, RRT, MortalityN.AAKINIn-hospital5Young^[@CR32]^New ZealandCombined48 vs 483 × 5 min/5 min at upper limb200 mmHgN.AYesAKI, RRT, Mortality1.10RIFLE30 d5Gallagher^[@CR22]^UKCABG43 vs 433 × 5 min/5 min at upper limb50 mmHg \> SBPN.AYesAKI, RRT, Mortality1.37AKIN30 d2Candilio^[@CR23]^UKCombined57 vs 542 × 5 min/5 min at upper limb and thigh200 mmHg\<45 minsYesAKI, RRTN.AAKINIn-hospital5Hong^[@CR33]^KoreaCombined644 vs 6364 × 5 min/5 min at thigh200 mmHgN.AYesAKIN.AAKINIn-hospital5Hu^[@CR34]^ChinaValve101 vs 1004 × 5 min/5 min at thigh600 mmHgPost-CPBYesAKI, Mortality0.83AKINIn-hospital4Pinaud^[@CR35]^FranceValve50 vs 493 × 5 min/5 min at upper limb200 mmHg91 minsYesAKI, RRTN.AAKINIn-hospital3Hausenloy^[@CR25]^UKCombined749 vs 7724 × 5 min/5 min at upper limb200 mmHg105 minYesAKI, RRT, MortalityN.AKDIGOIn-hospital5Zarbock^[@CR26]^GermanCombined120 vs 1203 × 5 min/5 min at upper limb200 mmHg or 50 mmHg \> SBPN.AYesAKI, RRT, Mortality1.15KDIGOIn-hospital5Meybohm^[@CR24]^GermanCombined692 vs 6934 × 5 min/5 min at upper limb≥200 mmHg or 15 mmHg \> SBPN.AYesRRT, MortalityN.ARIFLEIn-hospital5Cao^[@CR37]^ChinaValve30 vs 303 × 5 min/5 min at lower limb200 mmHgN.AYesRRTN.ARRTIn-hospital3Walsh^[@CR36]^Canada/US/India/ChinaCombined128 vs 1303 × 5 min/5 min at thing300 mmHgN.AYesAKI, RRT, Mortality1.07AKIN6 mon5Kim^[@CR27]^KoreaCombined80 vs 804 × 5 min/5 min at upper limb200 mmHg29.4 hYesAKI, RRT, Mortality0.9AKINIn-hospital5Note: RCT, randomized controlled trials; CABG, coronary artery bypass graft; I/R, ischemia/reperfusion; SBP, systolic blood pressure; atm, atmosphere; AKI, acute kidney injury; RRT, renal replacement treatment; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; N.A, not available; AKIN, Acute Kidney Injury Network; RIFLE, Risk, Injury, Failure, Loss of renal function and End-stage renal disease; KDIGO, Kidney Disease: Improving Global Outcomes; RIPC, remote ischemic preconditioning; Ctrl, control. Table 2Patient characteristics in all included randomized trials.SubstudyAgeMale (%)Pre-MI (%)DM (%)HT (%)Dyslipidemia (%)Renal dysfunction (%)CPB duration (min)Baseline LVEF (%)Complex Surgery (%)CABG (%)Volatile Anesthetic (%)Aspirin (%)ACEI (%)β-blockers (%)Statins (%)Rahman^[@CR17]^64.088.50.00.059.374.1N.A98.060.10.0100.098.188.364.880.990.7Thielmann^[@CR28]^63.785.037.70.092.584.9N.A109.51.5(\<35%)0.0100.0100.083.064.275.564.2Venugopal^[@CR19]^65.082.023.00.065.475.6N.A85.41.0(\<35%)14.196.061.566.765.455.079.5Zimmerman^[@CR18]^63.568.6N.A22.547.0N.A16.1(eGFR\<60)11410.2(\<35%)11.040.0100.0N.A14.0N.AN.AChoi^[@CR20]^58.539.523.57.09.0N.A11.0(eGFR\<60)138.561.523.50.0100.0N.A44.720.07.9Lomivorotov^[@CR29]^57.396.1N.A0.0N.AN.AN.A64.559.00.0100.0100.0N.A56.686.8N.ALucchinetti^[@CR30]^60.591.041.80.070.985.5N.A101.052.00.0100.0100.0N.A51.091.096.4Hong^[@CR31]^64.772.9N.A35.768.617.10.054.00.0(\<30.0%)0.0100.00.094.354.364.372.9Kim^[@CR21]^57.555.6N.A13.033.3N.A0.0127.564.548.10.0N.AN.A11.122.25.6Young^[@CR32]^66.462.527.8N.AN.A60.4N.A111.12.0(\<30.0%)31.357.3100.0N.A52.166.760.4Gallagher^[@CR22]^70.880.252.364.082.677.9N.A94.052.0/10.5(\<35%)5.896.587.296.579.135.0N.ACandilio^[@CR23]^65.578.128.729.278.874.20.093.24.5(\<30%)11.862.496.177.566.362.980.9Hong^[@CR33]^60.861.37.330.248.653.83.1159.757.019.750.8N.A48.339.142.7N.AHu^[@CR34]^47.137.80.00.00.0N.A0.081.30.0(\<35%)39.30.0100.0N.AN.AN.AN.APinaud^[@CR35]^74.451.50.014.177.853.5N.A81.465.60.00.0100.018.220.228.340.4Hausenloy^[@CR25]^76.270.839.525.774.569.80.070.011.6(\<35%)50.2N.A40.278.460.364.079.7Zarbock^[@CR26]^70.462.90.037.596.7N.A30.9118.015.0(\<35%)46.3N.A100.059.660.060.868.8Meybohm^[@CR24]^66.074.228.924.8N.AN.A11.2115.00.0(\<35%)27.2N.A2.7N.A52.763.265.5Cao^[@CR37]^53.048.3N.A0.0N.AN.AN.A115.051.0N.AN.AN.A0.0N.AN.A0.0Walsh^[@CR36]^72.258.529.430.6N.AN.A3.9137.6N.A32.257.083.7N.AN.AN.AN.AKim^[@CR27]^62.353.1N.A0.034.4N.A0.0230.958.536.36.30.0N.AN.AN.AN.ANote: Pre-MI, previous myocardial infarction; DM, diabetes mellitus; HT, hypertension; CPB, cardiopulmonary bypass; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass graft; ACEI, angiotensin-converting enzyme inhibitor; N.A, not available.

Effect of RIPC on the incidence of AKI, RRT, and Mortality {#Sec4}
----------------------------------------------------------

AKI was reported in 6054 study subjects, and the overall incidence was 25% (707/3017 in RIPC group, 777/3037 in control group). Postoperative incidence of AKI was significantly reduced by RIPC (17 RCTs; odds ratio (OR) = 0.79; 95% CI, 0.65 to 0.96; P = 0.02; I^2^ = 38%; Fig. [2A](#Fig2){ref-type="fig"}). There was no evidence of publication bias (Begg's test P = 0.22; Egger's test P = 0.32).Figure 2Forest plot of the effect on RIPC on (**A**) AKI and (**B**) AKI stage I.

For AKI, stage I the overall incidence was 19% (372/2122 in RIPC group, 439/2152 in control group). RIPC significantly reduced the risk of AKI stage I (11 RCTs; OR = 0.65; 95% CI, 0.47 to 0.89; P = 0.007; I^2^ = 55%; Fig. [2B](#Fig2){ref-type="fig"}) with no significant publication bias (Begg's test P = 0.19; Egger's test P = 0.08). There was no difference in the incidence of AKI stage II or stage III between the 2 groups as shown in Table [3](#Tab3){ref-type="table"}.Table 3Pooled analysis of the postoperative primary and second endpoints.EndpointsReferencesRIPCControlPts with complete dataOR (95% CI)WMD (95% CI)P valueAKI[@CR17]--[@CR27], [@CR31]--[@CR36]707/3017(23.4%)777/3037(25.6%)96.06%0.79(0.65, 0.96)/0.02AKI stage I[@CR17]--[@CR19], [@CR22]--[@CR27], [@CR32], [@CR36]372/2122(17.5%)439/2152(20.4%)67.79%0.65(0.47, 0.89)/0.007AKI stage II[@CR18], [@CR19], [@CR22]--[@CR27], [@CR32], [@CR36]105/2046(5.1%)100/2074(4.8%)65.38%1.07(0.81,1.42)/0.64AKI stage III[@CR17]--[@CR20], [@CR22]--[@CR33], [@CR35]--[@CR37]89/3013(3.0%)94/3034(3.1%)95.95%0.92(0.58,1.45)/0.71RRT[@CR17]--[@CR20], [@CR22]--[@CR33], [@CR35]--[@CR37]89/3013(3.0%)94/3034(3.1%)95.95%0.92(0.58,1.45)/0.71Mortality (30-day)[@CR17]--[@CR19], [@CR21], [@CR22], [@CR24], [@CR26]--[@CR29], [@CR31]--[@CR35]31/2079(1.5%)32/2073(1.5%)65.89%0.96(0.58, 1.61)/0.89Mortality (\<1 year)[@CR17], [@CR23], [@CR25], [@CR30], [@CR36]60/1069(5.6%)48/1097(4.4%)34.37%1.19(0.62, 2.29)/0.60MV duration[@CR17], [@CR20]--[@CR22], [@CR26]--[@CR29], [@CR31]--[@CR35]1330131742.00%/−0.77(−1.32, −0.23)0.005ICU stay[@CR17], [@CR20]--[@CR23], [@CR25]--[@CR29], [@CR31], [@CR33]--[@CR37]2277229372.52%/−0.23(−0.49, 0.02)0.07Hospital LOS[@CR17]--[@CR23], [@CR25]--[@CR28], [@CR31], [@CR33], [@CR34], [@CR36], [@CR37]2284230372.79%/−0.01(−0.28, 0.25)0.92Notes: AKI, acute kidney injury; RRT, renal replacement treatment; MV duration, mechanic ventilation duration; ICU stay, intensive care unit stay; Hospital LOS, hospital length of stay; Pts, patients; OR, odds ratio.WMD, weighted mean difference; CI, confidence interval; RIPC, remote ischemic preconditioning.

The RRT was reported in 6047 study subjects, and the overall incidence was 3% (89/3013 in RIPC group, 94/3034 in control group). The risk of postoperative RRT was not lowered in the RIPC group (19 RCTs; OR = 0.92; 95% CI, 0.58 to 1.45; P = 0.71; I^2^ = 37%; Table [3](#Tab3){ref-type="table"}).

The 30-day and 1-year mortality data were available in 4152 and 2166 patients and the mortality rates were 1.5% and 5% respectively. There was no significant difference between the RIPC group and the control group for both these endpoints as shown in Table [3](#Tab3){ref-type="table"}.

Effect of RIPC on MV duration, ICU stay, and hospital LOS {#Sec5}
---------------------------------------------------------

RIPC significantly shortened MV duration by 0.77 hours (13 RCTs; 95% CI, −1.32 to −0.23 hours; P = 0.005; I^2^ = 57%), and there was a trend towards reduced ICU stay by 0.23 days (16 RCTs; 95% CI, −0.49 to 0.02 days; P = 0.07; I^2^ = 96%) (Fig. [3](#Fig3){ref-type="fig"}). However, RIPC did not affect hospital LOS (16 RCTs; −0.01 days, 95% CI, −0.28 to 0.25 days; P = 0.92; I^2^ = 45%; Table [4](#Tab4){ref-type="table"}).Figure 3Forest plot of the effect on RIPC on (**A**) MV duration and (**B**) hospital length of stay. Table 4Meta-regression and Subgroup analyses for the potential sources of heterogeneity.VariablesEndpointNo. RCTsCovariateCoeff./OR/WMD95% CIP Value***Univariate**Coeff.**Adjusted R*** ^***2***^Age (years)AKI stage I11/0.060.02\~0.110.010.86HT (%)AKI stage I8/0.02−0.004\~0.040.090.49Additive ischemia (%)AKI stage I11/0.040.007\~0.070.020.93Complex surgery (%)AKI stage I11/0.020.002\~0.030.030.81***Multivariate**Coeff.**Adjusted R*** ^***2***^AgeAKI stage I9Previous MI (%)0.05−0.01\~0.100.091.00AKI stage I10Diabetes (%)0.060.005\~0.120.040.81AKI stage I8HT (%)0.070.01\~0.130.031.00Complex surgery (%)AKI stage I9Previous MI (%)0.02−0.001\~0.030.061.00AKI stage I10Diabetes (%)0.020.003\~0.0330.030.95***Subgroup**I*** ^***2***^***P*** ~***Difference***~ ***Value**OR***1. Age (years)AKI stage I11/0.650.47\~−0.890.00754.70%\<0.00001  ≥66.06/0.950.80\~1.130.580.00%  \<66.05/0.370.24\~0.58\<0.000010.00%2. Complex surgery (%)AKI stage I11/0.650.47\~−0.890.00754.70%0.005  ≥25%5/0.780.57\~1.080.1354.00%  \<25%6/0.430.27\~0.710.0010.00%Note: AKI, acute kidney injury; ICU stay, intensive care unit stay; HT, hypertension; previous MI, previous myocardial infarction; LVEF, left ventricular ejection fraction; Coeff., coefficient; WMD, weighted mean difference; CI, Confidence Interval.

Meta-regression and Subgroup analyses for Potential Sources of Heterogeneity {#Sec6}
----------------------------------------------------------------------------

Age, male, previous myocardial infarction (MI), diabetes, hypertension, dyslipidemia, renal dysfunction, cardiopulmonary bypass duration, baseline left ventricular ejection fraction, complex surgery, CABG, use of volatile anesthesia, aspirin, angiotensin-converting enzyme inhibitors, beta-blockers, and statins, cumulative duration of preconditioned ischemia, and additive ischemia were included in the random-effect univariate meta-regression analyses for AKI stage I. The major sources of heterogeneity were age (coefficient = 0.06; P = 0.01; adjusted R^2^ = 0.86), hypertension (coefficient = 0.02; P = 0.09; adjusted R^2^ = 0.49), additive ischemia (coefficient = 0.04; P = 0.02; adjusted R^2^ = 0.93), and complex surgery (coefficient = 0.02; P = 0.03; adjusted R^2^ = 0.81) as shown in Table [4](#Tab4){ref-type="table"}. Subsequent multivariate analyses showed that age (coefficient = 0.06; P = 0.01) and complex surgery (coefficient = 0.02; P = 0.03) remained significantly associated with AKI stage I, as shown in the meta-regression plots in Fig. [4](#Fig4){ref-type="fig"} and Table [4](#Tab4){ref-type="table"}. There was a relative reduction in the estimated effect size by 0.06 (natural transformation of OR) per 1-year increase in age and by 0.20 (natural log transformation of OR) per 10% increase in the proportion of complex surgery for AKI stage I by RIPC.Figure 4Meta-regression plots on the incidence of AKI stage I against (**A**) age and (**B**) proportion of complex surgery.

Subgroup analyses showed that RCTs with a mean age of \<66 years old had less risk of AKI stage I than those with a mean age of ≥66 years old \[OR: 0.37 versus 0.95, P \< 0.001 for subgroup difference; Table [4](#Tab4){ref-type="table"}\]. Furthermore, RCTs with the proportion of complex surgery being \<25% had significantly less AKI stage I than those with the proportion of complex surgery being ≥25% \[OR: 0.43 versus 0.78; P = 0.005 for subgroup difference; Table [4](#Tab4){ref-type="table"}\].

Discussion {#Sec7}
==========

In this meta-analysis of 21 RCTs involving 6302 adult patients undergoing cardiac surgery, we found that RIPC reduced the incidence of AKI. In addition, RIPC also shortened MV duration and there was a trend towards shorter ICU stay, but heterogeneity among the included RCTs was substantial for the latter. RIPC was more effective at reducing AKI stage I in RCTs with younger patients (\<66 years old) and in those RCTs with less complex cardiac surgery (\<25%). However, RIPC did not affect AKI stage II and III/requirement for RRT, hospital length of stay, and mortality.

Post-operative AKI in adult cardiac surgery is a common complication, occurring in up to a third of surgical cases^[@CR4],\ [@CR38],\ [@CR39]^. Even minor increase in postoperative serum creatinine level following cardiac surgery has been shown to be associated with increased MV duration^[@CR40]^, prolonged ICU stay^[@CR41]^, and the risk of short-term mortality^[@CR2],\ [@CR41],\ [@CR42]^. Although AKI can occur due to numerous reasons and the underlying mechanisms remain unclear, acute tubular necrosis has been implicated as being the predominant pathology^[@CR43]^. There is currently no effective renoprotective strategy to reduce the burden of AKI in this setting^[@CR44]^. Several RCTs have investigated the renoprotective effect of RIPC in patients undergoing cardiac surgery but with conflicting results. To minimize heterogeneity due to trial design and patient selection, our study only included RCTs involving adult cardiac surgery, but not in combination with major vascular surgery^[@CR45],\ [@CR46]^, pediatric cardiac surgery^[@CR46],\ [@CR47]^, percutaneous coronary intervention^[@CR47],\ [@CR48]^, or organ transplantation^[@CR47]^.

We found that RIPC reduced the incidence of AKI stage I and MV duration, and there was a trend towards shorter ICU stay. Our findings are consistent with the RCT by Zarbock *et al*.^[@CR26]^, which was specifically designed and powered to look at the effect of RIPC on AKI as the primary endpoint in 240 patients. Of note, they only included patients at high risk of AKI. Furthermore, they used volatile anesthesia instead of propofol, the latter of which may potentially attenuate the effect of RIPC^[@CR49],\ [@CR50]^. They showed a 15% and 10% absolute risk reduction in the incidence of AKI and the need for RRT, respectively. RIPC also reduced the duration of stay in ICU but there was no difference in overall hospital length of stay^[@CR26]^.

The risk of death is proportional to the severity of AKI, with the highest rate occurring in patients requiring RRT following adult cardiac surgery^[@CR4],\ [@CR51],\ [@CR52]^. In our analysis, the incidence of RRT was 3.1% and the 30-day mortality was only 1.5% (4152 patients), many of whom presented with normal preoperative serum creatinine level. RIPC did not affect the need for RRT or mortality in our analysis. Thielmann *et al*.^[@CR53]^ randomized 329 patients undergoing CABG and obtained similar findings to our study for 30-day mortality. However, they found that RIPC reduced 1-year mortality and the result remained significant after 4-year follow-up. Therefore, longer follow-up duration should be considered in future RCTs to see a benefit in mortality.

Translating renoprotective strategies that have shown promise in young and healthy animals into the clinical population with various co-morbidities and/or confounders (such as age^[@CR54],\ [@CR55]^, surgical complexity^[@CR56]^, and previous MI^[@CR57]^) has proven to be challenging. Our meta-regression analysis showed that age was negatively correlated with the reduction in AKI stage I by RIPC. Likewise, the proportion of complex surgery was negatively correlated with the reduction in AKI stage I. Based on the findings from our study and that of Zarbock *et al*.^[@CR26]^, whether pre-selecting a younger cohort of patients who are at risk of AKI, undergoing non-complex surgery using volatile anesthesia may more likely show a significant reduction in all stages of AKI by RIPC and eventually improve clinical outcomes, remain to be assessed in future, adequately powered RCTs.

There are several limitations in our study. Firstly, we were unable to access the patient-level data. Therefore, the potential influences of co-morbidities (diabetes^[@CR19]^, baseline left ventricular ejection fraction^[@CR57]^, and interval between coronary angiography and surgery^[@CR58]^) and cardiovascular medications (such as volatile anesthetics^[@CR59]^ and statins^[@CR60]^) may have been underestimated. Secondly, AKI was based on different definitions such as AKI Network classification (AKIN), Risk/Injury/Failure/Loss/End-stage (RIFLE) criteria or the Kidney Disease: Improving global Outcomes (KDIGO) classification^[@CR61],\ [@CR62]^, and the patient selection, type of surgery and RIPC protocol used were different and may have contributed to the heterogeneity. Thirdly, although we included several recently published large RCTs, the sample size was still relatively small to be adequately powered for hard clinical outcomes. Last but not least, only 11 RCTs qualified for the meta-regression analysis and therefore the conclusions may not be robust but hypothesis generating.

In conclusion, the available evidence from the present meta-analysis indicates that RIPC reduces the incidence of AKI in adults undergoing cardiac surgery and this benefit was more pronounced in younger patients undergoing non-complex cardiac surgery. RIPC may also shorten MV duration, and length of stay in ICU, and this warrants further investigation in future RCTs tailored for those most likely to benefit.

Methods {#Sec8}
=======

Search strategy and study criteria {#Sec9}
----------------------------------

This meta-analysis was performed according to the PRISMA statement^[@CR63]^ as shown in the flow chart in Fig. [1](#Fig1){ref-type="fig"}. We did a systematic search in PubMed, EMBase, and Cochrane Library (up to November 2016) using keywords "remote ischemic preconditioning", "remote ischaemic preconditioning", "ischemic preconditioning", "cardiac surgery", "heart surgery", "kidney", and "renal". Furthermore, editorials and references from included RCTs were manually searched. RCTs published in English and involving adult patients were included. Exclusion criteria were: (1) pediatric cardiac surgery; (2) studies not reporting acute kidney injury (AKI) and RRT during hospitalization.

Literature review and data extraction {#Sec10}
-------------------------------------

The literature review and data extraction were independently completed by two investigators (J.G. and Y.Z.). Any disagreements were resolved by consensus. Quality assessment was performed according to Jadad score: randomization; blinding; withdrawals and dropouts (a possible score between 0 and 5). Trials with a score of more than 3 were considered as being of high-quality^[@CR64]^. Data extraction included patient's age, male gender, history of MI, diabetes, hypertension, dyslipidemia, renal dysfunction, CPB duration, baseline LVEF, type of surgery (complex surgery defined as a combination of valve, CABG, or major vascular surgery), usage of volatile anesthesia, aspirin, angiotensin converting enzyme inhibitors, beta-blockers and statins. Cumulative duration of preconditioned ischemia was calculated multiplying the number of cycles by the ischemic duration (for example, 3\*5 min = 15 min for preconditioning with 3 × 5 min ischemia/5 min reperfusion). Additive ischemia^[@CR65]^ was calculated using cumulative duration of preconditioned ischemia relative to the CPB duration.

Postoperative Outcomes {#Sec11}
----------------------

The primary endpoints were incidence of AKI as a whole and AKI stage I--III individually, and the definition used by each RCT (AKIN, RIFLE, or KDIGO criteria^[@CR61]^) was used for this study.

The secondary endpoint included RRT (defined as dialysis or hemofiltration), mechanic ventilation (MV) duration, intensive care unit (ICU) stay, and hospital length of stay (LOS).

Statistical analysis {#Sec12}
--------------------

For dichotomous outcomes (reported as incidence), we calculated OR with 95% CI. For continuous outcomes (MV duration, duration of stay in ICU and hospital length of stay) reported as mean and standard deviation, the WMD for the pooled estimates with 95% CI were calculated. For RCTs reporting median and interquartile range, or median and range, the method described by Hozo *et al*.^[@CR66]^ was used to convert to mean and standard deviation. Random-effect model was used in view of differences in patient selection and the RIPC protocol used among the RCTs. Publication bias was assessed by Begg's test and Egger's test. Heterogeneity among RCTs was quantified using I^2^ statistics with I^2^ of 0--40%, 30--60%, 50--90% and 75--100% considered as low, moderate, substantial and considerable heterogeneity, respectively, as defined by the Cochrane handbook of systematic reviews^[@CR67]^ and moderate heterogeneity was considered acceptable. Meta-regression (P \< 0.1) and subgroup analysis were conducted for positive results to explore the potential sources of heterogeneity^[@CR68]^. To reduce the possibility of over-fitting in the multivariate regression model, at least four studies or sub-studies were set for the identification of each influential factor^[@CR69],\ [@CR70]^. P \< 0.05 (2-sided) was considered to be statistically significant. All statistical analyses were performed in Stata (version 9.0; Stata Corporation, College Station, TX).
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